Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 1, 1999, Pages 33-39

  Palkama, Vilja J ^a   Ahonen, Jouni ^a   Neuvonen, Pertti J ^a   Olkkola, Klaus T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; MIDAZOLAM; MIDAZOLAM MALEATE; SAQUINAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANTI-ANXIETY AGENTS; ANTI-HIV AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; HYPNOTICS AND SEDATIVES; INJECTIONS, INTRAVENOUS; MALE; MIDAZOLAM; REFERENCE VALUES; SAQUINAVIR; TIME FACTORS;

EID: 0032807936     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70051-2     Document Type: Article

References (22)

1. 1. Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clin Pharmacol Ther 1981;30:653-61.
2. 2. Heizmann P, Eckert M, Ziegler WH. Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 1983;16:S43-9.
3. 3. Wandel C, Böcker R, Böhrer H, Browne A, Rügheimer E, Martin E. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 1994; 73:658-61.
4. 4. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305.
5. 5. Yeates RA, Laufen H, Zimmermann T. Interaction between midazolam and clarithromycin: comparison with azithromycin. Int J Clin Pharmacol Ther 1996;34:400-5.
6. 6. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-5.
7. 7. Barry M, Mulcahy F, Back DJ. Antiretroviral therapy for patients with HIV disease. Br J Clin Pharmacol 1998;45: 221-8.
8. 8. Vella S, Floridia M. Saquinavir: clinical pharmacology and efficacy. Clin Pharmacokinet 1998;34:189-201.
9. 9. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997;44:190-4.
10. 10. Iribarne C, Berthou F, Carlhant D, Dreano Y, Picart D, Lohezic F, et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos 1998;26:257-60.
11. 11. Merry C, Mulcahy F, Barry M, Gibbons S, Back D. Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease. AIDS 1997;11:268-9.
12. 12. Ha HR, Rentsch KM, Kneer J, Vonderschmitt DJ. Determination of midazolam and its 1-hydroxymetabolite in human plasma and urine by high-performance liquid chromatography. Ther Drug Monit 1993;15:338-43.
13. 13. Stone BM. Pencil and paper tests: sensitivity to psychotropic drugs. Br J Clin Pharmacol 1984;18:15S-20S.
14. 14. Smith JM. Critical flicker frequency (CFF) and psychotrophic drugs in normal human subjects: a review. Psychopharmacology 1976;47:175-82.
15. 15. Hannington-Kiff JG. Measurements of recovery from out-patient general anaesthesia with a simple ocular test. Br Med J 1970;3:132-5.
16. 16. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974;47:211-8.
17. 17. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994;22:947-55.
18. 18. Olkkola KT, Ahonen J, Neuvonen PJ. The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996;82:511-6.
19. 19. Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994;37:221-5.
20. 20. Neuvonen PJ, Varhe A, Olkkola KT. The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clin Pharmacol Ther 1996;60:326-31.
21. 21. Kivistö KT, Lamberg TS, Kantola T, Neuvonen PJ. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 1997;62:348-54.
22. 22. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997;61:410-5.